IL1B and cancer: Importantly, these limitations stem from IL-1β’s pleiotropic mode of action.13 Selective delivery of IL-1β activity to CD8+ T cells might limit toxicity and undesired side effects, hence allowing application as a cellular adjuvant in cancer immunotherapy.